GlassScriptPhysician profile
Mantinderpreet Singh
NPI 1689089625
$10,004.52
in general payments reported to CMS, 2019-2025
41 companies · $974 in 2025
The $974 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $1,112 · 2021: $1,942 · 2022: $1,902 · 2023: $1,496 · 2024: $1,570 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,037 · Education: $1.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,037.23 |
| Education | $1.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,008.18 | 2019-2025 | |
| Biogen, INC. | $901.64 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Sk Life Science, INC. | $716.42 | 2020-2025 | Xcopri |
| Amneal Pharmaceuticals LLC | $663.93 | 2019-2025 | Rytary, Crexont, Ongentys |
| Ucb, INC. | $639.31 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Emd Serono, INC. | $561.37 | 2019-2023 | Mavenclad |
| Abbvie INC. | $533.99 | 2021-2025 | Qulipta |
| Lilly USA, LLC | $518.09 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Lundbeck LLC | $460.44 | 2022-2025 | Vyepti, Rexulti |
| Supernus Pharmaceuticals, INC. | $416.86 | 2019-2022 | |
| Eisai INC. | $401.93 | 2020-2025 | |
| Pfizer INC. | $360.21 | 2019-2025 | |
| Genzyme Corporation | $334.56 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $322.62 | 2021-2024 | Austedo Xr, Austedo, Ajovy |
| Amgen INC. | $300.93 | 2019-2025 | Aimovig, Uplizna |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $245.47 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $213.56 | 2019-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $177.27 | 2022-2024 | Ingrezza, Ongentys |
| Biohaven Pharmaceutical Holding Company LTD. | $147.42 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $131.79 | 2021 | |
| Sunovion Pharmaceuticals INC. | $123.67 | 2021-2022 | |
| Celgene Corporation | $110.88 | 2021-2024 | Zeposia |
| Neurelis, INC. | $106.10 | 2021-2025 | Valtoco |
| Acorda Therapeutics, INC | $87.23 | 2019 | |
| Tanabe Pharma America, INC. | $72.18 | 2021-2024 | |
| Allergan, INC. | $66.51 | 2019-2020 | |
| Kyowa Kirin, INC. | $55.31 | 2021-2024 | Nourianz |
| Upsher-Smith Laboratories LLC | $42.86 | 2020-2021 | |
| Corium, LLC | $40.89 | 2023 | Adlarity |
| Acadia Pharmaceuticals INC | $35.94 | 2021-2022 | |
| Argenx US, INC. | $33.08 | 2022-2023 | Vyvgart |
| E.R. Squibb & Sons, L.L.C. | $29.69 | 2021 | |
| Impel Pharmaceuticals INC. | $29.04 | 2022-2023 | Trudhesa |
| Sumitomo Pharma America, INC. | $19.41 | 2023 | Aptiom |
| Livanova USA, INC. | $18.64 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Scilex Pharmaceuticals INC. | $16.91 | 2025 | |
| Csl Behring | $15.83 | 2023 | Hizentra |
| Banner Life Sciences, LLC | $15.37 | 2023 | |
| Mallinckrodt Hospital Products INC. | $13.26 | 2021 | |
| Ge Healthcare | $11.25 | 2020 | |
| Kinex Medical Company LLC | $4.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mantinderpreet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.